<DOC>
	<DOCNO>NCT01303549</DOCNO>
	<brief_summary>The study randomize , open-label safety study compare use anidulafungin ( 200 mg i.v . initial dose 100 mg/d i.v . subsequent dos ) vs liposomal amphotericin B ( 3 mg/kg/d i.v . ) hepatic transplant recipient high risk fungal infection .</brief_summary>
	<brief_title>Anidulafungin v Amphotericin B Safety High Risk Hepatic Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>At least 18 year old Signature ICF Negative pregnancy test ( woman child bear potential ) Patients comply least one follow ( A B ) : A : One follow criterion ( major criterion ) : Retransplant due severe dysfunction previous hepatic graft Requirement renal substitutive therapy , include dialysis hemofiltration Fulminant hepatitis require hepatic transplant B : Two follow criterion ( minor criterion ) : Posttransplant renal impairment ( define CrCl &lt; 50 mL/min ) 30 day transplantation Intra surgery blood transfusion least 40 unit Choledochal jejunectomy 2 Candida sp culture ( nasal , pharynx , rectal ) 48 hour pre 48 hour posthepatic transplant Post transplant reintervention ( laparotomy ) Hypersensibility amphotericin B candin Patients receive antifungal ( exclude fluconazole oral nystatin maximum 7 day ) Documented suspected fungal infection Pregnant woman woman accept u valid anticonceptive method Any disease medical condition make patient adequate participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>Hepatic transplant</keyword>
	<keyword>Antifungal prophylaxis</keyword>
	<keyword>Anidulafungin</keyword>
	<keyword>Liposomal Amphotericin B</keyword>
</DOC>